International Journal of Contemporary Pediatrics

Vinod M et al. Int J Contemp Pediatr. 2024 Jun;11(6):862-864

http://www.ijpediatrics.com

pISSN 2349-3283 | eISSN 2349-3291

A rheumatological catastrophe: case of amyopathic juvenile dermatomyositis

Meghashree Vinod*, Nikitha K.


Department of Pediatrics, Mysore Medical College and Research Institute, Mysore, Karnataka, India

Received: 14 April 2024

Revised: 15 May 2024

Accepted: 20 May 2024

*Correspondence:

Dr. Meghashree Vinod,

E-mail: meghashreevinod@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Juvenile-onset amyopathic dermatomyositis is rare variant of juvenile-onset dermatomyositis (JDM), characterized by the hallmark cutaneous features of dermatomyositis without clinical or laboratory evidence of muscle disease. Dermatomyositis with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody has a distinct phenotype associated with small hand joint arthritis, mucocutaneous ulceration in the absence of muscle involvement. In this article, we describe a 5-year-old child presented with mucocutaneous manifestations with no muscle weakness who responded to immunosuppressive therapy.

Keywords: Amyopathic juvenile dermatomyositis, Anti-melanoma differentiation associated gene-5, Gottron’s papules

INTRODUCTION

Amyopathic juvenile-onset dermatomyositis (JDM) is also known as Dermatomyositis sine myositis. Children can have isolated skin disease or mild undetected muscle inflammation.1 A high index of suspicion is needed not to miss atypical presentations. Rare in paediatric age group. Long term complications include calcinosis, lipodystrophy, ILD.

CASE REPORT

A 5-year-old female child 1st born to non-consanguinous parents presented with hyperpigmented macular lesions and painful ulcers over upper and lower limbs predominantly involving extensor surface of bilateral elbow and knee joints since 20 days which was progressive in nature. There was no history of trauma. Child had no complaints of fever, weakness of limbs, arthralgia, difficulty in breathing or swallowing. Child is developmentally appropriate for age, immunised till date.

On physical examination, multiple healed hyperpigmented scars were present all over body. Ulcers approximately 6 × 5 cm were present over extensor surface of bilateral knee and elbow joints exposing underlying bone. Child showed violaceous papules on her interphalangeal joints (Gottron’s papules) and extensor aspect of forearms. Child had neither heliotrope rash nor erythema of sun exposed areas. Systemic examination was normal. Proximal and distal muscle strength of limbs were normal and no muscle tenderness was noted.

Investigations revealed normal hemogram and normal urine examination. Liver function test, renal function test was normal. ESR was 130 mm/hr, CRP-48 mg/l. Serum levels of muscle derived enzymes; LDH, CKMB, AST, ALT were normal. ANA profile was negative. Serologic testing was found to be anti MDA5 positive which was suggestive of amyopathic JDM. EMG was normal. HRCT thorax was normal. Blood culture showed no growth. Pus culture showed Staphylococcus aureus sensitive to gentamycin, clindamycin and linezolid. Skin and muscle biopsy were refused by the parents.

Figure 1: Ulcers measuring 6 × 5 cm over bilateral knee joints and multiple hyperpigmented gangrenous patches over lower limbs.
Figure 1: Ulcers measuring 6 × 5 cm over bilateral knee joints and multiple hyperpigmented gangrenous patches over lower limbs.
Figure 2: Ulcer over left knee joint with gangrenous changes exposing underlying bone.
Figure 2: Ulcer over left knee joint with gangrenous changes exposing underlying bone.
Figure 3: Gottron’s papules over interphalangeal joints.
Figure 3: Gottron’s papules over interphalangeal joints.

Surgical and orthopaedic consultation was taken. Wound debridement and regular dressings were done. Intravenous linezolid (15 mg/kg) for 7 days followed by oral clindamycin (10 mg/kg) was given for 7 days. Child was started on pulse therapy of methyl prednisolone (30 mg/kg) for 3 days which was followed by oral prednisolone 1 mg/kg. As skin ulcers did not improve over 10 days, IvIg (2g/kg) was given every 2 weeks for 3 months. Child was also started on oral methotrexate, folic acid, vitamin D, calcium supplementation and sunscreen lotion.

Methotrexate and prednisolone was tapered gradually over next 6 months. Occupational therapy given. Child was advised muscle flap surgery by reconstructive and cosmetic surgeon. Child was also advised 6 monthly follow up to monitor for cardiopulmonary involvement, muscle disease and relapse.

DISCUSSION

Juvenile-onset amyopathic dermatomyositis is an uncommon variant of juvenile-onset dermatomyositis (JDM), characterized by the hallmark cutaneous features of dermatomyositis for at least 6 months without clinical or laboratory evidence of muscle disease. Recent literature suggests that approximately 75% of amyopathic JDM patients will remain free from muscle disease after years of follow-up, while approximately 25% of patients will evolve to having classic JDM.2 No clinical, laboratory, or ancillary parameters have been found to be predictive for this transition to muscle disease.

The anti-melanoma differentiation-associated gene 5 (MDA5) antibodies (Abs), was originally identified in a specific subset of dermatomyositis, named clinically amyopathic DM (CADM), associated with an increased risk for rapidly progressive interstitial lung disease (RP-ILD). MDA5 is a cytosolic protein, essential for antiviral host immune responses, which functions as a virus RNA sensor and induces, once activated, the production of type I interferons (IFN-I) and pro-inflammatory cytokines by the cell. The pathogenic role of anti-MDA5 Abs is currently unknown.3 The clinical presentation of anti-MDA5 DM differs substantially from the other forms of DM, with three distinct clinical phenotypes, according to the predominance of pulmonary, skin-articular or vascular symptoms.4

Skin ulcerations associated with anti-MDA5 DM usually manifest as deep painful ulcers localized over Gottron’s papule, involving the digital pulp and nail folds on the knees, elbows, or both. The histology of skin ulcerations shows vasculopathy, pauci-inflammatory or characterized by medium vessel wall infiltration with mononuclear cells, and intravascular thrombus. Major complications can occur, such as gangrene and osteomyelitis, potentially leading to digital amputation.5,6

Anti-MDA5 DM is associated with poor prognosis due to a high prevalence of RP-ILD. ILD is the result of inflammation and fibrosis of the lung parenchyma and specific patterns of ground-glass attenuation are observed on high-resolution computed tomography. Anti-MDA5 Abs titers also correlate with the severity of the disease, and more particularly with the severity of ILD and cutaneous symptoms.7 Our patient despite of having severe cutaneous lesions, did not have evidence of ILD on HRCT.

Although no recommendations for the management of anti-MDA5 DM exist at this time, a combination immunosuppressive (IS) therapy is used. This intensive IS treatment classically consists of an association of glucocorticoids with a calcineurin inhibitor (cyclosporine A or tacrolimus) or a triple therapy with the addition of intravenous cyclophosphamide or mycophenolate mofetil.8

CONCLUSION

In conclusion, we are presenting a rare case of juvenile amyopathic JDM with extensive cutaneous lesions without features of ILD who responded to combined immunosuppressive therapy with prompt resolution of cutaneous lesions although reconstructive surgery was advised for joint involvement.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

  1. 1. Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2010;78(4):776-85.
  2. 2. Walling HW, Gerami P, Sontheimer RD. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management. Paediatr Drugs. 2010;12(1):23-34.
  3. 3. Nombel A, Fabien N, Coutant F. Dermatomyositis with Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol. 2021;12:773352.
  4. 4. Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different Phenotypes in Dermatomyositis Associated with Anti-MDA5 Antibody: Study of 121 Cases. Neurology. 2020;95:e70-8.
  5. 5. Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical Manifestations of Dermatomyositis and Clinically Amyopathic Dermatomyositis Patients with Positive Expression of Anti-Melanoma Differentiation-Associated Gene 5 Antibody. Arthritis Care Res. 2012;64:1602-10.
  6. 6. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The Mucocutaneous and Systemic Phenotype of Dermatomyositis Patients With Antibodies to MDA5 (CADM-140). J Am Acad Dermatol. 2011;65:25-34.
  7. 7. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care Res. 2016;68(5):689-94.
  8. 8. Romero-Bueno F, Diaz del Campo P, Trallero-Araguás E, Ruiz-Rodríguez JC, Castellvi I, Rodriguez-Nieto MJ, et al. Recommendations for the Treatment of Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. Semin Arthritis Rheum. 2020;50:776-90.